skip to content


Issue No. 28 | November 20, 2015

News and Features

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Now Included Among Recommended Regimens for Antiretroviral Treatment-Naive Individuals with HIV-1 Infection

The FDA recently approved the fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF) as a complete regimen for antiretroviral treatment (ART)-naive HIV-infected individuals 12 years or older. Based on efficacy and safety data from phase 3 randomized clinical trials, the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents will include EVG/c/FTC/TAF among the Recommended Initial Regimens for ART-naive adults and adolescents with estimated creatinine clearance ≥ 30 mL/min (AI). For more information, see the Panel’s statement on EVG/c/FTC/TAF.

HRSA Launches Survey on Adult and Adolescent ARV Guidelines

The Panel on Antiretroviral Guidelines for Adults and Adolescents and the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB) is committed to improving the Department of Health and Human Services (HHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. HAB has launched a survey to receive feedback on experiences with the guidelines.

The target audience are those staff that utilize the HIV treatment guidelines such as physicians, nurses, physician assistants (PAs), etc. It takes less than 15 minutes to complete the survey, and all responses will remain anonymous. The Guidelines Panel will use the feedback when producing future updates to the guidelines.

December 1 is World AIDS Day

December 1 is recognized globally as World AIDS Day. The annual observance highlights the remarkable advances in HIV prevention, treatment, and care since what became known as the AIDS epidemic was first reported three decades ago. World AIDS Day is also an occasion to reflect on the ongoing challenges to achieve an AIDS-free generation.

Visit our World AIDS Day webpage [en español] to learn more about this observance and to find HIV/AIDS-related information and resources.

NIH Launches Initiative to Develop Long-Acting HIV Treatment and Prevention Tools

"The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a major initiative to advance novel approaches to treat and prevent HIV infections based on broadly neutralizing antibodies (bNAbs) today. A public-private partnership has been established for this effort between NIAID and the global pharmaceutical company GlaxoSmithKline (GSK) to enable researchers to develop one or more bNAbs, which can stop a wide range of HIV strains from infecting human cells in the laboratory, into a product to treat or prevent HIV infection."
For more information, view the NIAID press release.